ProCE Banner Activity

Selecting Therapy for AML Without Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations

Slideset Download
Download these expert-selected slides on optimal treatment of patients with newly diagnosed AML without actionable mutations.

Released: December 04, 2020

Expiration: December 03, 2021

Share

Faculty

Alice Mims

Alice Mims, MD, MSCR

Associate Professor
Division of Hematology
Department of Internal Medicine
The Ohio State University
Columbus, Ohio

Provided by

Provided by National Comprehensive Cancer Network, in partnership with Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Agios Pharmaceuticals

Jazz Pharmaceuticals, Inc.

Pfizer, Inc.

Faculty Disclosure

Primary Author

Alice Mims, MD, MSCR

Associate Professor
Division of Hematology
Department of Internal Medicine
The Ohio State University
Columbus, Ohio